Top Suppliers:I want be here


387867-13-2

387867-13-2 structure
387867-13-2 structure
  • Name: Tandutinib (MLN518)
  • Chemical Name: Tandutinib(CT 53518)
  • CAS Number: 387867-13-2
  • Molecular Formula: C31H42N6O4
  • Molecular Weight: 562.703
  • Catalog: API Antineoplastic agents Tinic antineoplastic agents
  • Create Date: 2018-03-10 08:00:00
  • Modify Date: 2025-08-24 20:30:28
  • Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. IC50 value: 0.22 uM [1]Target: Flt3; PDGFRβ; c-Kitin vitro: Tandutinib has little activity against EGFR, FGFR, KDR, InsR, Src, Abl, PKC, PKA and MAPKs. Tandutinib inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM. Tandutinib also inhibits the proliferation of human leukemia Ba/F3 cells containing FLT3-ITD mutations with IC50 values of 10-30 nM, and the FLT3-ITD-positive Molm-13 and Molm-14 cells with an IC50 of 10 nM. In FLT3-ITD-positive Molm-14 cells but not the FLT3-ITD-negative THP-1 cells, Tandutinib treatment leads to significant apoptosis by 51% and 78% at 24 and 96 hours, respectively, due to specific FLT3 inhibition [1]. Tandutinib preferentially inhibits the growth of blast colonies from FLT3 ITD-positive compared with ITD-negative patients with AML, without affecting colony formation by normal human progenitor cells [2].in vivo: Oral administration of Tandutinib at 60 mg/kg bid significantly increases the survival in mice bearing Ba/F3 cells expressing W51 FLT3-ITD mutant, and gives a significant reduction in mortality in a mouse bone marrow transplantation model [1]. Tandutinib treatment at 180 mg/kg twice daily has mild toxicity toward normal hematopoiesis, however, it is a dose at which Tandutinib is effective in treating FLT3 ITD-positive leukemia in mice [2].

Name Tandutinib(CT 53518)
Synonyms 4-(6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide
MLN 518
Tandutinib
4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide
N-(4-Isopropoxyphenyl)-4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}piperazine-1-carboxamide
Tandutinib for research
1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-
N-(4-Isopropoxyphenyl)-4-{6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl}-1-piperazinecarboxamide
UNII:E1IO3ICJ9A
Unii-E1io3icj9a
Description Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. IC50 value: 0.22 uM [1]Target: Flt3; PDGFRβ; c-Kitin vitro: Tandutinib has little activity against EGFR, FGFR, KDR, InsR, Src, Abl, PKC, PKA and MAPKs. Tandutinib inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM. Tandutinib also inhibits the proliferation of human leukemia Ba/F3 cells containing FLT3-ITD mutations with IC50 values of 10-30 nM, and the FLT3-ITD-positive Molm-13 and Molm-14 cells with an IC50 of 10 nM. In FLT3-ITD-positive Molm-14 cells but not the FLT3-ITD-negative THP-1 cells, Tandutinib treatment leads to significant apoptosis by 51% and 78% at 24 and 96 hours, respectively, due to specific FLT3 inhibition [1]. Tandutinib preferentially inhibits the growth of blast colonies from FLT3 ITD-positive compared with ITD-negative patients with AML, without affecting colony formation by normal human progenitor cells [2].in vivo: Oral administration of Tandutinib at 60 mg/kg bid significantly increases the survival in mice bearing Ba/F3 cells expressing W51 FLT3-ITD mutant, and gives a significant reduction in mortality in a mouse bone marrow transplantation model [1]. Tandutinib treatment at 180 mg/kg twice daily has mild toxicity toward normal hematopoiesis, however, it is a dose at which Tandutinib is effective in treating FLT3 ITD-positive leukemia in mice [2].
Related Catalog
References

[1]. Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432.

[2]. Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104(9), 2912-2918.

[3]. Schittenhelm MM, et al. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle, 2009, 8(16), 2621-2630.

[4]. Salama Y, et al. The angiogenic factor Egfl7 alters thymogenesis by activating Flt3 signaling. Biochem Biophys Res Commun. 2017 Aug 19;490(2):209-216.

Density 1.2±0.1 g/cm3
Boiling Point 769.5±60.0 °C at 760 mmHg
Melting Point 177-178°C
Molecular Formula C31H42N6O4
Molecular Weight 562.703
Flash Point 419.2±32.9 °C
Exact Mass 562.326782
PSA 92.29000
LogP 3.48
Vapour Pressure 0.0±2.6 mmHg at 25°C
Index of Refraction 1.611
Storage condition Refrigerator
Hazard Codes T,N,Xi,F
Risk Phrases R25:Toxic if swallowed. R34:Causes burns. R50:Very Toxic to aquatic organisms. R40:Limited evidence of a carcinogenic effect. R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S23-S37-S45-S61-S36-S26-S16
RIDADR UN 1751 6.1/PG 2
WGK Germany 2
RTECS AF8575000
Packaging Group II
Hazard Class 6.1
HS Code 29154000
HS Code 29154000
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.